IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Dikstein et al.
Serial No. : 09/763,909
Filed : June 8, 2001
Title : A TRANSCRIPTION FACTOR TFIID SUBUNIT, TAFII105, POLYPEPTIDES, DNA ENCODING THEREFOR AND PHARMACEUTICAL COMPOSITIONS

Art Unit : 1642
Examiner : Minh-Tam B. Davis

Commissioner for Patents
Washington, D.C. 20231

RESPONSE TO RESTRICTION REQUIREMENT

Responsive to the action mailed December 3, 2002, Applicants respectfully traverse the restriction of Group I and Group XVI, as set forth below:

> Group I: Claims 1-2, 6, 12-13, 15-16, and 18-19, drawn to a DNA molecule encoding a fragment of the wild type TAF_{11} 105 polypeptide of SEQ ID NO:2 or a fragment of the wild type polynucleotide of SEQ ID NO:1, an expression vector comprising said DNA molecule, and an antisense of SEQ ID NO:1;
>
> Group XVI: Claim 17, drawn to a method for promotion of apoptosis, comprising administering an antisense sequence of SEQ ID NO:1.

I. TRAVERSAL AND REQUESTED JOINDER OF GROUPS I AND XVI.

Applicants respectfully request joinder of Groups I and XVI in the present invention as a search of the combined groups would not create an undue burden upon the Examiner. Applicants respectfully submit that a search of the subject matter of Group I would encompass searching antisense molecules of SEQ ID NO:1. A search of Group XVI would encompass a search of antisense molecules for SEQ ID NO:1 and methods of promoting apoptosis. Accordingly, Applicants respectfully submit that joinder of Group I and XVI in the present application would not create an undue search burden on the Examiner.